Clinical Trials

This study aums to determine whether various markers of vascular stability are predictive of clinical events (intracerebral hemorrhage or focal neurologic deficits). The study will alos determine the prevalence of vitamin D deficiency in patients with cavernous malformation and determine if vitamin D deficiency correlates with presenting classification (Hemorrhage, Focal Neurologic Deficit, Seizure, Asymptomatic state) or natural history (hemorrhage risk).

Investigators are trying to learn more about why cavernous malformations form. In addition, investigators are trying to determine which cavernous malformations might cause future symptoms and which ones may be more benign. To do this, investigators are trying to look at various lifestyle factors, medication use, and other medical problems and how they influence what happens over time

The purpose of this study is to assess if using holography/ Augmented Reality and 3D-printed models to visualize intracranial diseases and aid in patient education.

The purpose of this study is to set up the infrastructure for future clinical trials for patients with cavernous malformations. To do this we will be assessing the quality of MRI and data collection from patients with cavernous malformations across multiple sites in the country. At Mayo, we will be looking at new MRI "sequences" in addition to the usual sequences to see if that helps determine which cavernous malformations may bleed again.

The purpose of this study is to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use.

The aim of this study is to create a state-wide biorepository and resource center for cerebrovascular diseases in Florida. The Center will collect and store detailed phenotypic information, DNA, and other biofluids on affected subjects with diverse cerebrovascular conditions, including, but not limited to, ischemic stroke, transient ischemic attack (TIA), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), vascular dementia (VAD), anoxic brain injury, unruptured intracranial aneurysm (UIA), cavernous malformation, arteriovenous malformations (AVM), carotid and vertebral arterial dissections, symptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis, non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH), cerebral venous thrombosis (CVT), moyamoya disease, fibrosmuscular dysplasia (FMD), non-traumatic, angiography-negative subarachnoid ...